STAAR SURGICAL CO
Close on Oct 19, 2026
- Market cap
- $1.13B
- P/E (TTM)
- 312.6
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jul 3, 2026 | Aug 12, 2026 | After market close | $93.50M | $0.16 | $0.39 |
| Q1 FY2026 Ended Apr 3, 2026 | May 13, 2026 | After market close | $93.50M | $0.10 | $0.48 |
| Q4 FY2025 Ended Jan 2, 2026 | Mar 3, 2026 | After market close | $57.80M | $-0.37 | – |
| Q3 FY2025 Ended Sep 26, 2025 | Nov 5, 2025 | After market close | $94.70M | $0.18 | $0.68 |
| Q2 FY2025 Ended Jun 27, 2025 | Aug 6, 2025 | After market close | $44.30M | $-0.34 | $-0.30 |
| Q1 FY2025 Ended Mar 28, 2025 | May 7, 2025 | After market close | $42.60M | $-1.10 | $-0.53 |
| Q4 FY2024 Ended Dec 27, 2024 | Feb 11, 2025 | After market close | $49.00M | $-0.69 | – |
| Q3 FY2024 Ended Sep 27, 2024 | Oct 30, 2024 | After market close | $88.60M | $0.20 | $0.33 |
| Q2 FY2024 Ended Jun 28, 2024 | Aug 7, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 29, 2024 | May 7, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 29, 2023 | Jan 8, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on May 7, 2025, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| annualized SG&A run rate | as the Company exits fiscal 2025 | $225.00M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Staar Surgical filed with the SEC
STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K/A
STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
STAAR Surgical Reports Second Quarter 2026 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
STAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder Letter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
STAAR Surgical Issues Shareholder Letter
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement
Material agreement · Listing notice · Executive or director change · Other events · EX-99.1 to Form 8-K
STAAR Surgical Announces Preliminary Results of Special Meeting of Stockholders
Other events · EX-99.1 to Form 8-K
STAAR Surgical Announces Expiration of Go-Shop Period
Other events · EX-99.1 to Form 8-K
STAAR Surgical Announces Amendments to Alcon Merger Agreement
Material agreement · Other events · EX-99.1 to Form 8-K
STAAR Surgical Reports Third Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon
Other events · EX-99.1 to Form 8-K
Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders
Other events · EX-99.1 to Form 8-K
STAAR Surgical Announces Preliminary Net Sales Results for Third Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Alcon Merger Maximizes Value for
Regulation FD disclosure · EX-99.1 to Form 8-K
STAAR Surgical Publishes Presentation Highlighting Compelling, Certain Cash Value Offered by Alcon Merger
Regulation FD disclosure · EX-99.2 to Form 8-K
STAAR Surgical Reports Second Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
Alcon Agrees to Acquire STAAR Surgical
Material agreement · Other events · EX-99.1 to Form 8-K
STAAR Surgical Announces Appointment of Deborah Andrews as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Improved contrast sensitivity and night vision1,4,5
Regulation FD disclosure · EX-99.1 to Form 8-K
STAAR Surgical Announces $30 Million Share Repurchase Authorization
Other events · EX-99.1 to Form 8-K
STAAR Surgical Reports First Quarter 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
STAAR Surgical + EVO ICL Around the World FIRST QUARTER 2025 05
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
STAAR Surgical Announces Changes to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
STAAR Surgical Announces Realignment of Leadership Structure
Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
STAAR Surgical Announces Leadership Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
STAAR Surgical + EVO ICL Around the World FOURTH QUARTER AND FISCAL 2024 EARNINGS PRESENTATION
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
STAAR Surgical to Host Fourth Quarter and Fiscal Year 2024 Earnings Conference Call and Webcast on February 19, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
STAAR Surgical Reports Third Quarter 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K/A
Earnings Presentation OCTOBER 30, 2024 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K/A
STAAR Surgical Reports Third Quarter 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Earnings Presentation OCTOBER 30, 2024 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
STAAR Surgical Reports Second Quarter 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
STAAR Surgical + EVO ICL Around the World Second Quarter 2024 Earnings Presentation 5
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Success of U.S. market building initiatives
Regulation FD disclosure · EX-99.1 to Form 8-K
STAAR Surgical Reports First Quarter 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K